

# JENNIFER LE

PharmD, MAS, BCPS-ID, FIDSA, FCCP, FCSHP

Dr. Le is Professor of Clinical Pharmacy at the University of California at San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences. Her curriculum vitae, herein, describes her professional achievement during her academic career spanning 18 years.

---

9500 Gilman Drive, MC 0657, La Jolla, CA 92093-0657

[jenle@health.ucsd.edu](mailto:jenle@health.ucsd.edu), [leoffice@health.ucsd.edu](mailto:leoffice@health.ucsd.edu) and (858) 534 - 3692

<https://pharmacy.ucsd.edu/faculty/le>

<https://profiles.ucsd.edu/jennifer.le>

<http://linkedin.com/in/jennifer-le-3a8785101>

Zoom jenle, Skype jenleucsd, Twitter @idpedle, Research Gate, E-Scholarship

---

## FOUNDER AND CHIEF EXECUTIVE OFFICER

Le Organics Inc DBA Lêberry Bakery & Donut  
Pasadena, California

## PROFESSOR OF CLINICAL PHARMACY

University of California San Diego  
Skaggs School of Pharmacy and Pharmaceutical Sciences  
La Jolla, California

## DIRECTOR OF EXPERIENTIAL EDUCATION

Los Angeles and Orange County  
University of California San Diego  
Skaggs School of Pharmacy and Pharmaceutical Sciences

## DIRECTOR OF FACULTY MENTOR TRAINING PROGRAM

University of California San Diego  
Skaggs School of Pharmacy and Pharmaceutical Sciences

**FACULTY-IN-RESIDENCE**

Miller Children's & Women's and Long Beach Memorial Hospitals  
MemorialCare Health System, Long Beach, California

**ASSOCIATE PROFESSOR OF CLINICAL PHARMACY**

University of California San Diego  
Skaggs School of Pharmacy and Pharmaceutical Sciences  
La Jolla, California

**ASSISTANT PROFESSOR OF CLINICAL PHARMACY**

University of California San Diego  
Skaggs School of Pharmacy and Pharmaceutical Sciences  
La Jolla, California

**ASSOCIATE PROFESSOR OF CLINICAL PHARMACY**

Western University of Health Sciences, College of Pharmacy  
Pomona, California

**ASSISTANT PROFESSOR OF CLINICAL PHARMACY**

Western University of Health Sciences, College of Pharmacy  
Pomona, California

**ASSISTANT PROFESSOR OF CLINICAL PHARMACY (WITHOUT SALARY)**

University of California San Francisco, School of Pharmacy  
San Francisco, California

**BACHELOR OF SCIENCE, BIOLOGY**

University of California Los Angeles, Los Angeles, California

**DOCTOR OF PHARMACY**

University of California San Francisco, School of Pharmacy  
San Francisco, California

**PHARMACY PRACTICE RESIDENCY**

Long Beach Memorial and Miller Children's & Women's and Hospitals  
MemorialCare Health System, Long Beach, California

**MASTERS OF ADVANCED STUDIES, CLINICAL RESEARCH**

University of California San Diego, La Jolla, California

## BOARD CERTIFICATION

---

**BASIC CARDIAC LIFE SUPPORT & FIRST AID**, American Heart Association

**LICENSED PHARMACIST**, California Board of Pharmacy

**HUMAN RESEARCH SUBJECTS PROTECTION TRAINING CERTIFICATION**,

National Institutes of Health

**NATIONAL PROVIDER IDENTIFIER** 1356346035, National Plan & Provider

Enumeration System

**PHARMACY-BASED IMMUNIZATION DELIVERY CERTIFICATION**, American

Pharmacists Association

**BOARD CERTIFICATION IN PHARMACOTHERAPY**, Board of Pharmaceutical

Specialties

**ADDED QUALIFICATION IN INFECTIOUS DISEASES**, Board of Pharmaceutical

Specialties

**COLLABORATIVE INSTITUTIONAL TRAINING INITIATIVE** in The Protection of

Human Research Subjects and Good Clinical Practice

**BOARD RE-CERTIFICATION IN PHARMACOTHERAPY**, Board of

Pharmaceutical Specialties

**ADDED QUALIFICATION IN INFECTIOUS DISEASES**, Board of Pharmaceutical

Specialties

**CERTIFICATE OF COMPLETION**, Faculty Mentorship Training Program,

University of California San Diego Health Sciences Office of Faculty Affairs

**CERTIFICATE OF COMPLETION**, Faculty Leadership Academy, University of

California San Diego Office of Academic Affairs, Academic Personnel

Services

## AWARDS

---

### **MEMBERSHIP AWARD**

American College of Clinical Pharmacy for membership recruitment as

President of Southern California College of Clinical Pharmacy

### **RHO CHI HONOR SOCIETY**

Western University, College of Pharmacy

### **FACULTY SERVICE AWARD**

Western University, College of Pharmacy

### **ACADEMIC SENATE TRAVEL AWARD**

University of California San Diego

### **RESEARCH AWARD**

Complications Associated with *S. aureus* Bacteremia in Children

Long Beach Research Symposium

### **FELLOW OF AMERICAN COLLEGE OF CLINICAL PHARMACY**

### **BEST POSTER AWARD**

Vancomycin Pharmacokinetics and Dosage Requirements in Pediatric Cancer Patients, Fourth Regional Congress of Cancer and Blood Disorders of Childhood, Jordan Society of Oncology Pediatrics

### **FELLOW OF CALIFORNIA SOCIETY OF HEALTH-SYSTEMS PHARMACISTS**

### **RECOGNITION AWARD FOR OUTSTANDING MENTOR**

University of California San Diego, Faculty Mentor Program

### **FELLOW OF INFECTIOUS DISEASES SOCIETY OF AMERICA**

**STERNFELS PRIZE FOR DRUG SAFETY INNOVATION** <http://sternfelsprize.org/>

## **GRANTS**

---

**PFIZER, INC**, *Complications Associated with Outpatient Parenteral Antibiotic Therapy in Children*, Principal Investigator (8% effort) of Investigator-Initiated Study, \$32,125

**AMERICAN COLLEGE OF CLINICAL PHARMACY**, *Optimizing Outcomes of Gram-negative Infections with Translational Research*, Principal Investigator (20% effort) of Investigator-Initiated Study, \$20,000

**MEMORIAL MEDICAL CENTER FOUNDATION**, *Treatment outcomes of urinary tract infection caused by multi-drug resistant Enterobacteriaceae*, Principal Investigator (5% effort) of Investigator-Initiated Study, \$3,120

**ASTELLAS**, *Effects of Delayed Initiation of Antifungal Therapy in Critically-Ill Neonates with Invasive Candidiasis*, Principal Investigator (5% effort) of Investigator-Initiated Study, \$40,948

**MEMORIAL MEDICAL CENTER FOUNDATION**, *Correlation Between Risk Factors and Outcomes in Critically Ill Infants with Invasive Candidiasis*, Principal Investigator (5% effort) of Investigator-Initiated Study, \$3,330

**MEMORIAL MEDICAL CENTER FOUNDATION**, *Longitudinal Surveillance of Antibiotic-Resistant Pathogens Causing Nosocomial Infections: Epidemiologic and Clinical Implications*, Principal Investigator (2% effort) of Investigator-Initiated Study, \$18,720

**CUBIST**, *Complications associated with Staphylococcus aureus bacteremia*, Principal Investigator (20% effort) of Investigator-Initiated Study, \$50,252

**NATIONAL INSTITUTES OF HEALTH: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES**, *Pharmacokinetics-pharmacodynamics of antimicrobials in pediatric resistant infections (K23)*, Principal Investigator (75-80% effort) of Investigator-Initiated Study, \$604,250

**NATIONAL INSTITUTES OF HEALTH: EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT**, *Developmental and Translational Pharmacology of Pediatric Antimicrobial Therapy (U54)*, Co-Investigator (5% effort) of Investigator-Initiated Project, \$3,734,148

**JMI LABORATORIES**, SENTRY Antimicrobial Surveillance Program, Principal Investigator (2% effort) of Investigator-Initiated Study, \$80,000

**NATIONAL INSTITUTES OF HEALTH: EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT**, *Pharmacokinetics of Understudied Drugs Administered to Children per Standard of Care*, Co-Investigator(20% effort) of Investigator-Initiated Project, \$486,700

**PRIVATE DONOR**, *Ceftaroline Pharmacokinetics in Children with Cystic Fibrosis*, Co-Investigator (10% effort) of Investigator-Initiated Study, \$20,000

**NATIONAL INSTITUTES OF HEALTH: EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT**, *Developing Pediatric Clinical Pharmacologists for the Advancement of Therapeutics (T32)*, Co-Investigator (5% effort) of Investigator-Initiated Project, \$828,245

**NATIONAL INSTITUTES OF HEALTH: EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT**, *Specialized Centers in Research in Pediatric Developmental Pharmacology (RPDP, U54)*, Co-Investigator (5% effort) of Investigator-Initiated Project, \$3,872,907

**NATIONAL INSTITUTES OF HEALTH: EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT**, *Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care (POPS) III*, Site Principal Investigator (Subcontract with Duke University, 20% effort) of Investigator-Initiated Project, \$4,545

**NATIONAL INSTITUTES OF HEALTH: EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT**, *Pediatric Trials Network's Antibiotic Safety in Infants with Complicated Intra-abdominal Infections (PTN SCAMP Task Order #25)*, Site Principal Investigator (Subcontract with Duke University, 20% effort) of Investigator-Initiated Project, \$138,023

**NATIONAL INSTITUTES OF HEALTH: EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT**, *Longitudinal Assessment of Beta-lactam Antibiotic Exposure in Critically-Ill Children with Sepsis in the PICU to Predict Dosing Requirements (RO1)*, Co-Investigator of Investigator-Initiated Project (14% effort), \$1,885,634

## RESEARCH

---

Pilot Study of Discrepancy Errors in the Medication-Use System, Principal Investigator of Investigator-Initiated Study

Evaluation of the Management of Pyelonephritis in Obstetric Patients, Principal Investigator of Investigator-Initiated Study

Retrospective Study of Insulin Management in Diabetic Obstetric Patients, Co-Investigator

Safety and Tolerability of Amphotericin B Use in Neonates, Principal Investigator of Investigator-Initiated Study

Evaluation of Disseminated Diseases in Neonates with Invasive Candidiasis, Principal Investigator of Investigator-Initiated Study

Prospective Study and Implementation of Medication Reconciliation Process, Co-Investigator

Analysis Adverse Drug Reactions in Hospitalized Pediatrics Patients over a 10-Year Period, Principal Investigator of Investigator-Initiated Study

Evaluation of Appropriate Use of Vancomycin with the Calculation of Defined Daily Dose, Principal Investigator of Investigator-Initiated Study

Impact of Initial Antibiotic Treatment on the Development of ESBL Infections in Neonates, Principal Investigator of Investigator-Initiated Study

Risk Factors and Appropriateness of Antibiotic Therapy in Hospitalized Patients with Healthcare-Associated Pneumonia, Principal Investigator of Investigator-Initiated Study

Characterization of Prior Antibiotic Use and Risk of Acquisition of Imipenem-Resistant *Acinetobacter baumannii*, Principal Investigator of Investigator-Initiated Study

Evaluation of a Revised Pediatric Vancomycin Pharmacokinetic Guideline in the Treatment of Presumed or Confirmed Methicillin-Resistant *Staphylococcus aureus* (Investigator-initiated study), Co- Investigator

Hepatotoxicity Associated with Fluconazole in Critically-ill Infants, Principal Investigator of Investigator-Initiated Study

Cough and Cold Medications Use in Children: Pharmacists' Perspectives, Principal Investigator of Investigator-Initiated Study

Combination Antifungal Therapy in Children, Principal Investigator of Investigator-Initiated Study

Medication Errors in Children and Adults: A Comparative Study, Principal Investigator of Investigator-Initiated Study

Role of Hospital Discharge Education by Pharmacists, Principal Investigator of Investigator-Initiated Study

Augmented Renal Clearance in Children: Vancomycin Pharmacokinetic Modeling, Principal Investigator of Investigator-Initiated Study

Risk Factors Associated with Augmented Renal Clearance in Children, Principal Investigator of Investigator-Initiated Study

---

**American Society of Health-System Pharmacists**

**American Pharmaceutical Association**

**California Society of Health-System Pharmacists**

**American College of Clinical Pharmacy**, Infectious Diseases and Pediatrics Pharmacy Research Network

**American Association of Colleges of Pharmacy**  
**Southern California Chapter of College of Clinical Pharmacy**  
**California Pharmacists Association**  
**Society of Infectious Diseases Pharmacists**  
**Central Los Angeles Pharmacists Association**  
**American Society of Microbiology**  
**Infectious Disease Association of California**  
**Infectious Diseases Society of America (Full Member)**  
**PK/PD Anti-Infectives Study Group of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID)**

## **B O A R D**

---

**INVITED EDITORIAL BOARD MEMBER**, Infectious Diseases Section, Pediatric Pharmacotherapy, Editors Milap Nahata and Sandra Caballero, American College of Clinical Pharmacy

**SECTION EDITOR**, Infectious Diseases Section, Pediatric Pharmacotherapy, American College of Clinical Pharmacy, 2013 (Chapter 45, 708-717)

**INVITED EDITORIAL FACULTY PANEL CHAIR**, Pediatric Self-Assessment Program (PedSAP) 2016 Book 1 (Immunology), American College of Clinical Pharmacy

**INVITED EDITORIAL BOARD MEMBER**, Pharmacotherapy, Areas of Expertise in Pediatrics, Infectious Diseases, Pharmacokinetics, and Pharmacodynamics American College of Clinical Pharmacy

**INVITED EDITORIAL BOARD MEMBER**, *Pediatric Medicine* (Open-Access Journal)

## **& A D V I S O R Y B O A R D**

---

**CONSULTANT**, Infectious Diseases for Network of Advisors (c/o Clinical Advisors), New York, NY

**CONSULTANT AND MEMBER OF SPEAKERS BUREAU**, Infectious Diseases for Pfizer Pharmaceuticals (Eraxis®, V-fend®, Zyvox®), New York, NY

**EDITORIAL ADVISORY BOARD MEMBER**, California Society of Health-System Pharmacists

**CONSULTANT**, Antimicrobial Stewardship for Children's Hospital of Orange County, Orange, CA

**CONSULTANT**, Compass Point Research, Nashville, TN

**BIostatistician AND CLINICAL ANALYST**, Compass Point Research, Nashville, TN

**CONSULTANT**, National Science Centre, Poland

**MEMBER**, SDPharmNet, San Diego, CA

**CONSULTANT**, Therapeutic Drug Monitoring, Hospital for Tropical Diseases, Ho Chi Minh, Viet Nam

**CONSULTANT**, Pharmacy Operations, Children's Hospital #2, Ho Chi Minh City, Viet Nam

**CONSULTANT**, Antibiotic Stewardship at Long An General Hospital, Ho Chi Minh City, Viet Nam

**INVITED ADVISORY BOARD MEMBER**, *Infectious Diseases and Therapy Journal*

**INVITED ADVISORY BOARD MEMBER**, Antimicrobial Drugs Advisory Committee, United States Food and Drug Administration

**INVITED ADVISORY BOARD MEMBER**, Asian Pacific Health Foundation

**CONSULTANT**, Therapeutic Drug Monitoring, University Medical Center, Ho Chi Minh, Viet Nam

**EXPERT WITNESS**, Pharmacology & Toxicology, Klinedinst Law Orange County Office

**INVITED EXPERT PANEL MEMBER**, Pediatric ECMO Anticoagulation Collaborative (PEACE) Consensus

## BOOK REVIEW

---

Pharmacotherapy

Journal of the American Pharmacists Association (JAPhA)

Formulary

Pediatric Infectious Diseases Journal

Critical Care Medicine

Feature Coordinator for California Journal of Health-Systems Pharmacist

Childhood Obesity Continuing Education Program

Residency Pearls

Journal of Global Infectious Diseases

Infectious Diseases (Book 9), Pharmacotherapy Self-Assessment Program, Seventh Edition

Journal of Antimicrobial Chemotherapy

Clinical Therapeutics

Journal of Pharmacokinetics and Pharmacodynamics

Journal of Pediatric Infectious Diseases

Expert Review of Anti-infective Therapy

Antimicrobial Agents and Chemotherapy

Infectious Diseases and Therapy Journal

Journal of Clinical Pharmacy and Therapeutics

Journal of Global Antimicrobial Resistance



Annals of Internal Medicine  
Clinical Infectious Diseases

---

Medical Research Council, South Africa  
National Science Centre, Poland  
National Institutes of Health, Special Emphasis Panel/Scientific Review Group, Respiratory Sciences - Small Business Study Section  
National Institutes of Health, Study Section Microbiology and Infectious Diseases  
Agency for Healthcare Research and Quality, Healthcare Patient Safety and Quality Improvement Research  
American Institute of Biological Sciences (AIBS), Scientific Peer Advisory and Review Services

---

**ABSTRACT REVIEWER**, California Society of Health-System Pharmacist  
**ABSTRACT REVIEWER**, American Pharmacists Association (APhA)  
**PROGRAM REVIEWER**, Pharmacogenomics Education Program (PharmGenEd™), Expert Reviewer for Asthma  
**PROMOTION FILE REVIEWER**, Faculty Promotion Review for Loma Linda University and Western University  
**PROGRAM REVIEWER**, American College of Clinical Pharmacy Self-Assessment Program (SAP)  
**PROGRAM REVIEWER**, American College of Clinical Pharmacy: Self-Assessment for Board Re-certification Programs including Pediatrics (PedSAP), Ambulatory Care (ACSAP), Pharmacotherapy (PSAP), Cardiology, Pulmonology and Transplantation  
**ABSTRACT REVIEWER**, Infectious Diseases Society of America, ID Week Resistance Mechanism  
**PROMOTION FILE REVIEWER**, Faculty Promotion Review for University at Buffalo School of Pharmacy and Pharmaceutical Sciences

## **SERVICE IN PROFESSIONAL COMMITTEES**

---

**VOLUNTEER**, California Society of Health-System Pharmacists Seminar  
**FACULTY ADVISOR**, South-Bay Long Beach Society of Health-System Pharmacists, Quiz Bowl  
**CHAIR**, Awards and Scholarship Committee, Southern California College

of Clinical Pharmacy

**MODERATOR**, California Society of Health-System Pharmacists Seminar

**PRESIDENT-ELECT**, Southern California College of Clinical Pharmacy

**PRESIDENT**, Southern California College of Clinical Pharmacy

**FOUNDER AND COORDINATOR**, Southern California Infectious Diseases Pharmacists Working Group

**PAST PRESIDENT**, Southern California College of Clinical Pharmacy

**FOUNDER AND CHAIR-ELECT**, Southern California College of Clinical Pharmacy Infectious Diseases Pharmacists Working Group

**CHAIR**, Taskforce for Expert Opinion Paper on Aerosolized Antibiotics Society of Infectious Disease Pharmacists

**INITIATOR AND DEVELOPER**, Awards and Recognition Program, Southern California College of Clinical Pharmacy

**FACULTY VOLUNTEER**, 27<sup>th</sup> Annual Western States Conference

**MEMBER**, Awards Committee, American College of Clinical Pharmacy

**INITIATOR AND DEVELOPER**, Awards Committee, Southern California College of Clinical Pharmacy

**CHAIR**, Southern California College of Clinical Pharmacy Infectious Diseases Pharmacists Working Group

**ALTERNATE-DELEGATE**, House of Representatives, Orange County Society of Health-System Pharmacists

**INVITED TASKFORCE MEMBER**, Program on Faculty Recruitment, Retention and Enrichment Sponsored by American Association of Colleges of Pharmacy

**REPORT CONTRIBUTOR AND INVITED GUEST TO DEAN'S COUNCIL, ARTICIPANT**, ACPE Focused Site Visit at Western University

**EDITORIAL ADVISORY BOARD MEMBER**, California Society of Health-System Pharmacists

**PARTICIPANT**, Focused-Investigator Training Program, American College of Clinical Pharmacy Research Institute

**CHAIR**, Aerosolized Antimicrobials Taskforce for Society of Infectious Diseases Pharmacists

**MEMBER**, California Society of Health-System Pharmacists Editorial Advisory Board

**INVITED GUEST**, Graduate Education/Training in Experimental Pharmacotherapeutics Summit, American Association of Colleges of Pharmacy

**CO-CHAIR**, Awards Committee, Southern California College of Clinical Pharmacy

**CHAIR AND LEAD CONTRIBUTOR**, Faculty Orientation and Development Information Guide, UCSD Skaggs School of Pharmacy - Faculty Development and Mentorship Committee

**SECRETARY & TREASURER**, American College of Clinical Pharmacy,  
Infectious Diseases Practice and Research Network

**APPOINTED MEMBER**, Board of Pharmacy Specialties in Infectious Diseases  
Pharmacy Practice Analysis Taskforce

## SERVICE

### UNIVERSITY OF CALIFORNIA SAN DIEGO

---

**MEMBER**, Faculty Development Committee, Comprehensive Exam Committee, Research Interest Group, Admissions Committee, Education Policy and Academic Oversight Committee

**CO-CHAIR**, Faculty Development and Mentorship Committee

**MEMBER**, Campus-wide Associated Health Professions Education Committee, Library Committee, Comprehensive Exam Committee, Subcommittee of Educational Policy (CEP) for Microbiology/Immunology, Student Summer Research Committee, Research Interest Group, Education Policy and Academic Oversight Committee

**CO-CHAIR**, Faculty Development and Mentorship Committee

**MEMBER**, Campus-wide Associated Health Professions Education Committee, Comprehensive Exam Committee, Student Summer Research Committee, Member, Education Policy and Academic Oversight Committee, Campus-wide Committee for Master of Advanced Studies, Clinical Research Program Review, *Ad Hoc* Pharm.D./Ph.D. Committee

**CO-CHAIR**, Faculty Development and Mentorship Committee

**MEMBER**, Campus-wide Associated Health Professions Education Committee, Comprehensive Exam Committee, Student Summer Research Committee, Education Policy and Academic Oversight Committee, Campus-wide Committee for Master of Advanced Studies in Clinical Research Program Review, Donor Stewardship Committee, *Ad Hoc* Search Committee for Dean Skaggs School of Pharmacy, *Ad Hoc* Pharm.D./Ph.D. Committee, *Ad Hoc* Search Committee for Faculty Position in Economics, Social and Administrative Sciences

**CO-CHAIR**, Faculty Development and Mentorship Committee

**MEMBER**, Campus-wide Associated Health Professions Education Committee, Faculty Awards Sub-committee, Comprehensive Exam Committee, Student Summer Research Committee, Education Policy and Academic Oversight Committee, Donor Stewardship Committee

**CHAIR**, Campus-wide Associated Health Professions Education

**CHAIR**, Faculty Awards Committee

**CO-CHAIR**, Faculty Development and Mentorship Committee

**MEMBER**, Faculty Awards Committee, Comprehensive Exam Committee,

Student Summer Research Committee, Education Policy and Academic Oversight Committee, *Ad Hoc* SSPPS Research Retreat Planning Committee, *Ad Hoc* Pharm.D./Ph.D. Committee

**CHAIR**, Campus-wide Associated Health Professions Education

**CHAIR**, Faculty Awards Committee

**CO-CHAIR**, Faculty Development and Mentorship Committee

**MEMBER**, Comprehensive Exam Committee, SSPPS APPE/IPPE Course Committee (Sub-Committee for Committee on Educational Policy),

Student Summer Research Committee, Education Policy and Academic Oversight Committee, *Ad Hoc* SSPPS Research Retreat Planning Committee

**CHAIR**, Faculty Awards Committee

**CHAIR**, Assessment Committee

**MEMBER**, Committee on Educational Policy, Committee on Academic Personnel, Comprehensive Exam Committee, Student Summer Research Committee, International Collaboration and Education

**CHAIR**, Assessment Committee

**CHAIR**, ACPE Self-Study on Educational Outcomes and Assessment

**MEMBER**, ACPE Self-Study Steering Committee, Committee on Academic Personnel, Student Summer Research Committee, International Collaboration and Education, SSPPS APPE/IPPE Course Committee (Sub-Committee for Committee on Educational Policy), Ad-hoc Committee for Fourth-Year Appraisal

**MEMBER**, Committee on Educational Policy, Committee on Academic Personnel, Student Summer Research Committee, International Collaboration and Education, SSPPS APPE/IPPE Course Committee (Sub-Committee for Committee on Educational Policy), and Health Sciences Associated Health Professionals Education Committee (AHPEC)

**CHAIR**, Committee on International Pharmacy Education and Research

**CHAIR**, Faculty Search for Psychiatry and Drug Abuse

**MEMBER**, Committee on Educational Policy, Committee on Academic Personnel, Student Summer Research Committee

**CHAIR**, Committee on International Pharmacy Education and Research

**MEMBER**, Committee on Educational Policy, Committee on Academic Personnel, Student Summer Research Committee

## **WESTERN UNIVERSITY, COLLEGE OF PHARMACY**

---

*Note: Member services were excluded*

**CHAIR**, Scholarship Recognition and Award Committee

**CHAIR**, Faculty Orientation, Enhancement, and Development

**CHAIR**, Ad hoc Post-Faculty Retreat Committee

**PROGRAM REVIEWER**, EdScholar Implementation

**CHAIR**, Faculty Orientation, Enhancement, and Development

**CHAIR**, ACPE Self-Study - Faculty Development Committee

**SECRETARY**, Faculty Meetings

**PROGRAM REVIEWER**, E-portfolio Implementation

**CHAIR**, Pharmacy Faculty Assembly

**MEMBER**, Dean's Council and Committee for College of Pharmacy Mission Statement

**CHAIR**, Faculty Orientation, Enhancement, and Development

**ASSESSOR**, Peer Formative Assessment of Teaching Program

**MEMBER**, Mentorship Program

## CENTER SERVICES AND COMMITTEES

---

**FACULTY-IN-RESIDENCE**, Long Beach Memorial and Miller Children's & Women's Hospitals of Long Beach, MemorialCare Health System

**INVITED PARTICIPANT**, Strategic Planning Committees for Missing Medications, Customer Service, Clinical Programs, Emergency Department & Technician Program, Long Beach Memorial and Miller Children's & Women's Hospitals of Long Beach

Women's Hospitals of Long Beach, MemorialCare Health System

**INITIATOR**, Inpatient Infectious Diseases Pharmacy Services, Long Beach Memorial and Miller Children's & Women's Hospitals of Long Beach,

**MEMBER**, Antimicrobial Stewardship Committee, Children's Hospital of Orange County

**MEMBER**, Epidemiology Committee, Miller Children's Hospital

**MEMBER**, Residency Oversight Committee, Long Beach Memorial Medical Center and Miller Children's Hospital

**CONTRIBUTOR**, PGY-1 Residency Re-accreditation Report, Long Beach Memorial Medical Center

**MEMBER**, Residency Advisor Council, University of California San Diego Medical Center

**MEMBER**, Memorialcare Health System, Academic Advisory Council

**SCIENTIFIC REVIEWER**, Memorialcare Health System Institutional Review Board

**MEMBER**, Clinical Research Operations Task Force, Memorialcare Health

**MEMBER**, Clinical Research Operations Implementation Task Force Memorialcare Health System

**MEMBER**, Clinical Research Managers Task Force, Memorialcare Health

**MEMBER**, pSCANNER Research Planning Roundtable, Memorialcare Health System

**MEMBER**, Hospital Discharge and Transitional Care Pharmacist Program, Long Beach Memorial Hospital

**MEMBER**, Long Beach Memorial Residency Advisory Committee

## PROGRAMS ESTABLISHED

---

**INITIATOR AND DEVELOPER**, Chemotherapeutic Agents Ordering and Monitoring Process, Long Beach Memorial Medical Center

**DEVELOPER**, Revision of Instructor and Block Evaluations Western University of Health Sciences, College of Pharmacy

**DEVELOPER**, Adult Digoxin Dosing Guideline for Pharmacist-Regulated Therapies, Long Beach Memorial Medical Center

**CONTRIBUTOR**, Best Practice Guideline for the Management of Pyelonephritis in Pregnant, Women Long Beach, Orange Coast, Saddleback and Anaheim Memorial Medical Centers

**DEVELOPER**, Medication Reconciliation Program Long Beach Memorial Medical Center and Miller Children's Hospital

**INITIATOR AND DEVELOPER**, Cefepime in Neutropenic Pediatric Patients Miller Children's Hospital

**INITIATOR AND DEVELOPER**, Vancomycin Drug Utilization Evaluation Long Beach Memorial Medical Center

**CONTRIBUTOR**, Maternal and fetal outcomes in the management of diabetic obstetric patients Long Beach Memorial Medical Center

**INITIATOR AND DEVELOPER**, Adult intravenous Vancomycin Guideline for Pharmacist-Regulated Therapies Long Beach Memorial Medical Center

**INITIATOR, DEVELOPER AND DIRECTOR**, PGY-1 Pharmacy Practice Residency with Emphasis in Education and Research (in affiliation with UC San Diego) Long Beach Memorial Medical Center

**INITIATOR AND DEVELOPER**, Clinical Pharmacist in the Emergency Department Long Beach Memorial Medical Center and Miller Children's

**CONTRIBUTOR**, University-wide Orientation Program Western University

**INITIATOR AND DEVELOPER**, Antibigram Supplement Long Beach Memorial Medical Center and Miller Children's Hospital

**DEVELOPER AND ASSESSOR**, Peer Formative Assessment of Teaching Western University of Health Sciences, College of Pharmacy

**CONTRIBUTOR**, Mentorship Program (for Faculty Members) Western University of Health Sciences, College of Pharmacy

**CONTRIBUTOR**, Implementation of E-testing for *S. aureus* isolates and Implementation of modified Hodge's Test screening for KPC Long Beach Memorial Medical Center and Miller Children's Hospital

**INITIATOR AND DEVELOPER**, Antibigram, Neonatal Antifungal and Sepsis Guidelines, Neutropenic Sepsis and Antifungal Guidelines, Restricted Antimicrobial Use Policy Children's Hospital of Orange County

**INITIATOR AND DEVELOPER**, Team-based Teaching and Medicine (APPE)  
Lesson Plan Long Beach Memorial Medical Center

## INTERNATIONAL SERVICES

---

**PARTICIPANT**, Health Fair Expo at Long Beach Memorial Medical Center

**COORDINATOR**, Pharmacy Booth, Miller Children's Annual Health Fair

**COORDINATOR**, Poison Control Booth, Baby Expo, Long Beach Memorial Medical Center

**JUDGE**, Final Posters, Pharmacy Technician Poster Competition, American University of Health Sciences

**COORDINATOR**, Health Fair in El Monte for Hypertension and Diabetes Screening (APhA) and Ask Your Pharmacist (NCPA)

**ADVISOR**, Summer Volunteer Program for High School and Pre-Pharmacy Students (Ivilynn Bui, Tri Tran, Gabriela Rodriguez, Tiana Vo, Austin Nguyen, Kelsey Schmidt, Andy Vo, and Alexandra Gionta), Long Beach Memorial

**COLLABORATOR**, Food Insecurity Project, University of Wisconsin School of Pharmacy

**PROGRAM INITIATOR AND DEVELOPER**, Vancomycin Therapeutic Monitoring, Oxford University Clinical Research Unit and Hospital for Tropical Diseases in Viet Nam

**PROGRAM INITIATOR AND DEVELOPER**, Aminoglycosides Therapeutic Monitoring, Oxford University Clinical Research Unit and Hospital for Tropical Diseases in Viet Nam

**PROGRAM INITIATOR AND DEVELOPER**, Access to Human Papilloma Virus Vaccine, Oxford University Clinical Research Unit in Viet Nam

**PROGRAM INITIATOR AND DEVELOPER**, Vancomycin & Aminoglycosides Therapeutic Monitoring, University Medical Center, Ho Chi Minh City, Viet Nam

---

## LOCAL

Gram-Positive Bacterial Infections: Pattern of Resistance and New Treatment, Long Beach Memorial Medical Center, 1 ACPE

Faculty Retreat: Reframing Our Vision, Western University

Ursodiol in the Treatment of Gallstones, Western University

Management of Candidemia: Focus on New Therapies, Southern California College of Clinical Pharmacy, 1 ACPE

Fungal Diseases for the Clinician with a Focus on Candida Infection, Long Beach Memorial Medical Center, 1 CME



Disseminated Candidiasis in Neonates, Long Beach Research Symposium  
Risk Factors and Treatment of Candidemia, Pacific Hospital  
Acute Otitis Media and the Role of Community Pharmacists, Orange  
County of Pharmacists Association, 1 ACPE  
Acute Otitis Media, University of Southern California Physician Assistant  
Program  
Fungal Infections in the Changing Hospital Environment, Pacific Hospital  
Burden of MRSA Infection – Focus on HA-MRSA, Pacific Hospital  
Antifungal Guidance: Management Strategies and Practice Guideline,  
Pacific Hospital  
Update on Antifungal Agents, Pacific Hospital  
Residency Seminar Series: Database Management, Statistical Analysis and  
Referencing for Research Projects  
Residency Seminar Series: Teaching Opportunities During Residency  
Residency Seminar Series: Career in Academia  
Residency Seminar Series: Effective Precepting of Pharmacy Students  
During Acute Care Rotation  
Long Beach Memorial Medical Center & Miller Children's Hospital  
Is A Career in Pharmacy Right for You?, Muir's Eventual Doctors University  
of California, San Diego  
Residency Seminar Series: Academia and Pediatric Research  
Residency Seminar Series: Generating Hypothesis in Research  
Residency Seminar Series: Effective Precepting of Pharmacy Students  
Residency seminar series: Study Design and Research Hypothesis  
Residency Seminar Series: Database Management, Statistical Analysis and  
Referencing for Research Projects  
Residency Seminar Series: Precepting Pearls and Assessment & Academic  
Pharmacy  
Long Beach Memorial & Miller Children's and Women's Hospitals  
Academic Pharmacy in Pediatric Infectious Diseases: *From Bedside to*  
*Research and Back*, UC San Diego Pre-Pharmacy Society  
Optimizing Drug Dosing in Pediatrics Through Clinical Pharmacology, Rady  
Children's Hospital of San Diego, Research Seminar Series  
Career in Academic Pharmacy: Pediatric Infectious Diseases, UCSD Alpha  
Epsilon Delta Pre-Health Society, Annual Health Professional Symposium  
Academic Pharmacy: Focus in Pediatric Pharmacology Research, UCSD  
Alpha Epsilon Delta Pre-Health Society, General Meeting  
Optimizing Antimicrobial Therapy in the Neonatal Intensive Care Unit:  
Clinical and Research Pharmacy at Southern California Association of  
Neonatal Nurses

## STATE



CAL-OPTIMA Asthma Training, CAL-OPTIMA, 2 ACPE

Community Pharmacists in the Management of Pediatric Infectious Diseases, California Pharmacists Association, 1.5 ACPE

Update on Treatment of Candidemia, California Pharmacists Association, 1.5 ACPE

What Are You Doing to Treat and Prevent MRSA in Your Institution? - Discussion Panel, California Society of Health-System Pharmacists Seminar, 1 ACPE

Therapeutic Drug Monitoring of Antimicrobial Agents in Children, California Society of Health-System Pharmacists Seminar, 1 ACPE

### **NATIONAL**

Urinary Tract Infections During Pregnancy (manuscript invited for CE), Annals of Pharmacotherapy, 1 ACPE

Management of Bacterial Rhinosinusitis (manuscript invited for CE), American Journal of Managed Care, 2 CME/ACPE

Therapeutic Management of Bronchitis (manuscript invited for CE), American Journal of Managed Care, 2 CME/ACPE

Following the Curve: Pharmacokinetic Guided-Dosing of Antimicrobials in Pediatrics, American College of Clinical Pharmacy, 1 ACPE

Antimicrobial Dosing Challenges in Children, Making-a-Difference in Infectious Diseases, 1 ACPE

Vaccines Update: Meningococcal B and Pneumococcal, Making-a-Difference in Infectious Diseases, 1 ACPE

Translating Evidence into Practice: Vancomycin Nephrotoxicity in Pediatrics, American College of Clinical Pharmacy, 1 ACPE

Best Practices for Pediatric Dosing Strategies: Ahead of the curve! Optimizing Vancomycin Dosing with Pharmacokinetic Modeling, American College of Clinical Pharmacy, 1 ACPE

What is Standard for Adding Drug to Pediatric Formulary: Institutions, Systems and PBMs?, American College of Clinical Pharmacology, 1 ACPE

Optimizing Vancomycin Dosing with Pharmacokinetic Modeling: Focus in Pediatrics, Vietnamese American Medical Association & Southern California Vietnamese Physicians Association, Garden Grove, CA, 1 ACPE

Optimizing Vancomycin and Aminoglycoside Dosing in Neonatal and Pediatric Patients on Extracorporeal Life Support (VancoAG-ECLS), Pediatric Acute Lung Injury and Sepsis Investigators (PALISI), Coronado, San Diego

Vancomycin Pharmacology in Pediatric Patients on ECMO, Extracorporeal Life Support Organization, Scottsdale, Arizona

PK/PD Applications in Stewardship, Making-a-Difference in Infectious Diseases, Orlando, Florida, 1 ACPE/CME

Experience and Challenges with Vancomycin Monitoring by AUC at ID Week by Infectious Diseases Society of America and Pediatric Infectious Diseases Society, Washington DC, 1 ACPE/CME  
Monitoring Vancomycin: Don't Gamble on the Therapeutic Window at American Society of Health System Pharmacist, Las Vegas, NV, 1 ACPE/CME

### **INTERNATIONAL**

Vancomycin Dosing in Children by Area-Under-the Curve (AUC), Interscience Conference on Antimicrobial Agents and Chemotherapy, 0.5 ACPE  
Therapeutic Drug Monitoring in Children, School of Pharmacy Ho Chi Minh City, Viet Nam  
Vancomycin: Therapeutic Drug Monitoring in Children and Adults, Hospital for Tropical Diseases, Ho Chi Minh City, Viet Nam  
Antimicrobial Dosing Challenges in Pediatric Patients, Pediatric Pharmaceutical Care Workshop in Children's Hospital of Chinese Medical University, Taichung, Taiwan  
Professional Development and Training in Pediatric Infectious Diseases: Clinical Pharmacists and Students, Pediatric Pharmaceutical Care Workshop in Children's Hospital of Chinese Medical University, Taichung, Taiwan  
The Art and Science of Clinical Pharmacy and Its Current Trend in Research: Pediatric Antimicrobial Stewardship, Grand Rounds, Children's Hospital of Chinese Medical University, Taichung, Taiwan  
Pneumonia: Science of Selecting Antimicrobials for CAP, HAP, VAP, & HCAP, Chinese Medical University, Taichung, Taiwan  
Case-Based Seminar on Clinical Pharmacists and Inpatient Medical Care: Pediatric Infectious Diseases, Grand Rounds, Children's Hospital of Chinese Medical University, Taichung, Taiwan  
(Presenting) and Publishing Patient-Oriented Research, Children's Hospital of Chinese Medical University, Taichung, Taiwan  
Pharmacokinetics and Pharmacodynamics of Anti-infection Agents in Pediatrics, Children's Hospital of Chinese Medical University, Taichung, Taiwan  
Non-HIV Viral Infections, Chinese Medical University, Taichung, Taiwan  
Academic File for Advancement of Clinical Faculty, Chinese Medical University, Taichung, Taiwan  
Pharmacology of Aminoglycosides, Hospital for Tropical Diseases Centre for Tropical Medicine and Global Health, Ho Chi Minh City, Viet Nam

Aminoglycoside Therapeutic Drug Monitoring, Hospital for Tropical Diseases Centre for Tropical Medicine and Global Health, Ho Chi Minh City, Viet Nam

Antimicrobial Dosing Challenges in Pediatric Patients, Hospital for Tropical Diseases Centre for Tropical Medicine and Global Health, Ho Chi Minh City, Viet Nam

Pharmacokinetics and Pharmacodynamics of Anti-infection Agents in Pediatrics, Hospital for Tropical Diseases Centre for Tropical Medicine and Global Health, Ho Chi Minh City, Viet Nam

Clinical Preceptorship: Train-the-Trainer Program, Chinese Medical University, Taichung, Taiwan

Clinical Preceptorship: Train-the-Trainer Program, Taiwan Medical University Taipei, Taiwan

Optimizing Vancomycin Dosing with Pharmacokinetic Modeling and Bayesian Estimation, Chinese Medical University, Taichung, Taiwan

What is Standard for Adding Drug to Pediatric Formulary: Institutions, Systems and PBMs?, Hospital for Tropical Diseases Centre for Tropical Medicine and Global Health Ho Chi Minh City, Viet Nam

Generic Antibiotics: Improved Use Using Systematic Clinical Pharmacology, Chengdu Food and Drug Administration, San Diego, CA

Therapeutic Equivalent Evaluations: US Formulary System, Chengdu Food and Drug Administration, San Diego, CA

Therapeutic Drug Monitoring (TDM)

Vancomycin & Aminoglycosides TDM

Vancomycin Dosing in Children by AUC

TDM Workshop

University Medical Center, District 5, Ho Chi Minh City, Viet Nam, 8 CE

## **DIDACTIC**

### **UNIVERSITY OF CALIFORNIA SAN DIEGO**

---

#### **LECTURER**

SPPS 202A Concepts in Pharmacy Practice: Research

SPPS 212A Therapeutics I: Clinical Pharmacokinetics and Pharmacokinetic Alterations in Special Populations

SPPS 212B Therapeutics II: Digoxin Pharmacokinetics

SPPS 212C Therapeutics III: Mood Stabilizer and Anticonvulsant Pharmacokinetics Pharmacokinetics

**ORAL EXAMINER**, SPPS 212B & 212C Therapeutics

**PRE-CONFERENCE CO-FACILITATOR**, SPPS 212C Therapeutics

**COURSE CO-CHAIR (COORDINATOR)**, SPPS 212C Therapeutics

**LECTURER**, Infectious Diseases Pharmacotherapy Review

### **LECTURER**

SPPS 208 Study Designs: Pharmacokinetics Study Designs

SPPS 249 Principles of Pharmacology and Physiology: Aminoglycosides, Beta-Lactams and Vancomycin

### **LECTURER**

SPPS 212A Therapeutics I: Clinical Pharmacokinetics and Pharmacokinetic Alterations in Special Populations

SPPS 212B Therapeutics II: Digoxin Pharmacokinetics

SPPS 212C Therapeutics III: Mood Stabilizer and Anticonvulsant Pharmacokinetics Pharmacokinetics

Infectious Diseases Pharmacotherapy Review

SPPS 246 Medical Microbiology and Infectious Diseases Therapeutics: Pediatric Infections, Pneumonia, Vancomycin and Aminoglycosides Clinical Pharmacokinetics and Non-HIV Viral Infections

SPPS 249 Principles of Pharmacology and Physiology: Aminoglycosides

**LECTURER**, SPPS 201 Immunization Training Course: Varicella, Herpes Zoster, Tetanus, Diphtheria, Pertussis, Dtap/Tdap, Hep A & B, HPV, Meningococcal, Measles, Mumps, Rubella, Hib Vaccine, Polio, Rotavirus, Zika

**FACILITATOR**, Flu immunizations for SSPPS Faculty and Staff by Students

**EXAMINER**, Multi-Station Objective Structured Clinical Examination (OSCE)

**FACILITATOR**, Interprofessional Objective Structured Clinical Examination

**FACILITATOR**, Flu immunizations for SSPPS Faculty and Staff by Students

SPPS 212D Therapeutics IV in Infectious Diseases: Infectious Disease Overview, Drug-Bug Review of Antibacterial Agents, Pediatric Infections, Pneumonia, Vancomycin and Aminoglycosides Clinical Pharmacokinetics and Non-HIV Viral Infections

**COURSE CO-CHAIR (COORDINATOR)**, SPPS 212A Therapeutics

**COURSE CO-CHAIR (COORDINATOR)**, SPPS 212D Therapeutics

### **DIDACTIC**

### **WESTERN UNIVERSITY COLLEGE OF PHARMACY**

### **LECTURER**

PHRM 5501 Pharmacokinetics: Drug Dosing in Renal Diseases ; Pharmacokinetic Alterations in Special Populations – Children, Geriatrics, and Obesity ; Drug Dosing in Cardiovascular Diseases, Pharmacokinetic Drug Interactions, Therapeutic Drug Monitoring

PHRM 6204 Pharmacy Practice: Digoxin Pharmacokinetics

PHRM 6202 Pharmacy Practice: Fluids & Electrolytes

PHRM 6205 Pharmacy Practice: Comprehensive Case Presentation ; Digoxin Pharmacokinetics Review ; Review of Fluid & Electrolytes & TPN

PHRM 6206 Pharmacy Practice: Case Study (Asthma, Contraception, DVT/PE, Acne)

PHRM 6207 Pharmacy Practice: Theophylline Pharmacokinetics

PHRM 6210 Foundation: Case presentation – Respiratory Diseases and Total Parenteral Nutrition - Focus on Calculations

PHRM 6301 Pharmacy Practice: Otitis Media, Pediatric Infectious Diseases

PHRM 6302 Pharmacy Practice: Vancomycin & Aminoglycosides Pharmacokinetics

Comprehensive Review: Review of Calculations and Applied Pharmacokinetics

**COURSE CHAIR**, PHRM 5501 *Pharmacokinetics* and PHRM 6206 Pharmacy Practice: Respiratory & Endocrine Diseases

**WORKSHOP LEADER AND FACILITATOR**

PHRM 5501 Pharmacokinetics: Workshops 1 – 8

PHRM 6206 Pharmacy Practice: Case Study (Asthma, Contraception, DVT/PE, Acne)

PHRM 6210: Comprehensive Case Study

PHRM 6301 Pharmacy Practice: Case Study (*Pneumonia, Cellulitis*)

PHRM 6306: Comprehensive Case Study (*Leukemia, Tumor Lysis Syndrome, Anemia/Thrombocytopenia, Neutropenic Fever*)

**EVALUATOR AND CASE FACILITATOR**

PHRM 5501 Pharmacokinetics: Block orientation, review, quiz and examination

PHRM 5113 Pharmacy Practice: Objective Structured Clinical Evaluation

PHRM 6205 Foundation: Objective Structured Clinical Evaluation

PHRM 6210 Pharmacy Practice: Objective Structured Clinical Evaluation, Comprehensive Case (*Depression, Hypertension, Anemia, Hypothyroidism*)

PHRM 6306 Pharmacy Practice: Objective Structured Clinical Evaluation

**EXPERIENTIAL**

---

**PRECEPTOR**, Acute Care Medicine APPE for 83 Pharmacy Students from Western University and UC San Francisco, Long Beach Memorial Hospital

**PRECEPTOR**, Infectious Diseases and Pharmacokinetics Rotation for 32 PGY-1 Residents and International Pharmacists, Long Beach Memorial Hospital

**INITIATOR AND DEVELOPER**, Los Angeles and Orange County Experiential Program for UC San Diego Pharmacy Students, Completed 24 New Site Affiliations and Procured over 145 Advanced Pharmacy Practice Experiences (APPE)

**PRECEPTOR**, Acute Care Medicine APPE for over 50 Students from UC San Diego, Long Beach Memorial Hospital,

**DIRECTOR**, Los Angeles and Orange County Experiential Program for UC San Diego Pharmacy Students

## RESIDENT & FACULTY MENTORSHIP

---

**RESEARCH MENTOR**, Mentored over 50 UC San Diego Pharmacy and Medical Students (including T32 and T35 Awardees)

**RESEARCH MENTOR**, Mentored 14 Western University Pharmacy Students

**POST-GRADUATE RESEARCH MENTOR**, Mentored 40 PGY-1 Pharmacy Practice Residents at Long Beach Memorial and Miller Children's & Women's Hospitals and UC San Diego

**RESEARCH ADVISOR**, Guided 10 Pre-Pharmacy & High School Students

**CAREER ADVISOR**, Guided over 12 UC San Diego Pharmacy Students

**FACULTY MENTOR**, Mentored 10 Pharmacists with Interest in Academic Career and Scholarly Activities (University of California San Diego, University of Nebraska, University of California Irvine, Midwestern University – Glendale)

---

Elstner E, Linker-Israeli M, Umiel T, **Le J**, et al. Combination of a potent 20-epi-vitamin D<sub>3</sub> analogue (KH1060) with 9-cis-retinoic acid irreversibly inhibits clonal growth, decreased bcl-2 expression, and induces apoptosis in HL-60 leukemic cells. *Cancer Research* 1996;56:3570-3576. [Original laboratory research]

Elstner E, Linker-Israeli M, **Le J**, et al. Synergistic decrease of clonal proliferation, induction of differentiation and apoptosis in APL cells after combined treatment with novel 20-epi vitamin D<sub>3</sub> analogs and 9-cis retinoic acid. *J Clin Invest* 1997;99:349-360. [Original laboratory research]

de Vos S, Dawson MI, Holden S, **Le J**, et al. Effects of retinoid x receptor-selective ligands on proliferation of prostate cancer cells. *The Prostate* 1997;32:115-121. [Original laboratory research]

Asou H, Koike M, Elstner E, Cambell M, **Le J**, et al. 19-nor vitamin D analogs: a new class of potent inhibitors of proliferation and inducers of differentiation of human myeloid leukemia cell lines. *Blood*. 1998;92:2441-9. [Original laboratory research]

**Le Jennifer**, Nguyen T, Law A, Hodding J. Adverse drug reactions in pediatrics over a 10-year period. *Pediatrics* 2006;118:555-562. [Original clinical research; Role – conceived, analyzed, wrote and supervised entire study]

**Le Jennifer**, Nguyen T, Okamoto M, Lieberman JM. Impact of empiric antibiotic use on the development of infections caused by extended-spectrum beta-lactamase bacterial pathogens in the neonatal intensive care unit. *Pediatric Infectious Diseases Journal* 2008;27:314-318. [Original clinical research]



- Le Jennifer**, Adler-Shohet FC, Nguyen C, Lieberman JM. Nephrotoxicity associated with conventional amphotericin B in neonates. *Pediatric Infectious Diseases Journal* 2009;28:1061-3. [Original clinical research]
- Le Jennifer**, Castanheira M, Burgess DS, McKee B, Iqbal R and Jones RN. Clonal Dissemination of *Klebsiella pneumoniae* Carbapenemase KPC-3 in Long Beach, California. *J Clin Microbiol.* 2010;48(2):623-5. [Case series]
- Le Jennifer**, SanAgustin M, Tran T and Adler-Shohet FC. Complications associated with outpatient parenteral antimicrobial therapy in children. *Clinical Pediatrics (Phila)* 2010;49:1038-43. [Original clinical research]
- Le Jennifer**, Bookstaver B, Rudisill C, Hashem M, Iqbal R, James C, and Sakoulas G. Treatment of meningitis caused by vancomycin-resistant *Enterococcus faecium*: high-dose and combination daptomycin therapy. *Annals of Pharmacotherapy* 2010;44(12):2001-6. [Case series]
- McKamy S, Hernandez E, Jahng M, Moriwaki T, Deveikis A and **Le Jennifer**. Incidence and risk factors influencing the development of vancomycin nephrotoxicity in children. *J of Pediatrics* 2011;158(3):422-6. [Original clinical research]
- Wang MK, Tran T, Tran V, Padilla L and **Le Jennifer**. Case-control study of risk factors and outcomes associated with neonatal candidiasis. *Journal of Neonatal-Perinatal Medicine* 2011;4:39-43. [Original clinical research]
- Le Jennifer**, McKee B, Srisupha-olarn W and Burgess DS. *In vitro* activity of carbapenems alone and in combination with amikacin against extended-spectrum beta-lactamase (ESBL)-producing bacteria with reduced carbapenem susceptibility. *Journal of Clinical Medicine Research* 2011;3(3):106-110. [Original research]
- Law AV, Jackevicius C, Murray WI, Hess K, Pham DQ, Min DI, and **Le Jennifer**. Impact of a faculty orientation and development committee. *American Journal of Pharmaceutical Education* 2012; 76 (1) Article 3. [Original clinical research]
- Kook JL, Chao SR, **Le Jennifer** and Robinson PA. Impact of the use of procalcitonin assay in hospitalized adult patients with pneumonia at a community acute care hospital. *Infect Control Hosp Epidemiol* 2012;33(4):424-426. [Original clinical research]
- Le Jennifer**, Bradley JS, Murray W, Romanowski GL, Tran TT, Nguyen N, et al. Improved vancomycin dosing in children using area under the curve exposure. *Pediatric Infectious Diseases Journal* 2013;32(4):e155-63. [Original clinical research]
- Le Jennifer**, Tran TT, Bui I, Wang MK, Vo A, Adler-Shohet FC. Time to Initiation of Antifungal Therapy for Neonatal Candidiasis. *Antimicrobial Agents and Chemotherapy* 2013;57(6):2550-55. [Original clinical research]
- Dugan S, **Le Jennifer**, Jew RK. Maximum tolerated osmolarity for peripheral administration of parenteral nutrition in pediatric patients. *JPEN Journal of Parenteral and Enteral Nutrition* 2013; 38(7):847-51. [Original clinical research]
- Tran TT, El-Hbiary S, Tindula R, Rai N, Nguyen A, and **Le Jennifer**. Unique pharmacist competency program at community-based, teaching hospitals. *Journal of Hospital Administration* 2013; 2(3):119-23. [Original clinical research]

Hill SE, Iqbal R, Cadiz CL, and **Le Jennifer**. Foodborne botulism treated with heptavalent botulism antitoxin. *Ann Pharmacother* 2013;47(2):e12. [Case report]

**Le Jennifer**, Vaida F, Nguyen E, Adler-Shohet FC, Romanowski GL, Kim J, Vo T, Capparelli EV. Population-based pharmacokinetic modeling of vancomycin in children with renal impairment. *Journal Pharmacol Clin Toxicol* 2014;2(1):1017-27. [Original clinical research]

Tremoulet A, **Le Jennifer**, Poindexter B, Sullivan JE, Laughon M, Delmore P, Salgado A, Chong SI, Melloni C, Gao J, Benjamin DK Jr, Capparelli EV, and Cohen-Wolkowicz M; on behalf of the Administrative Core Committee of the Best Pharmaceuticals for Children Act — Pediatric Trials Network. Characterization of the population pharmacokinetics of ampicillin in neonates using an opportunistic study design. *Antimicrob Agents Chemother* 2014;58(6):3013-3020. [Original clinical research]

**Le Jennifer**, Ngu B, Bradley JS, Murray W, Nguyen A, Nguyen L, Romanowski GL, Vo T, and Capparelli EV. Accuracy of vancomycin monitoring in children using Bayesian estimation. *Therapeutic Drug Monitoring* 2014;36(4):510-8. [Original clinical research]

Jackevicius CA, **Le Jennifer**, Nazer L, Hess K, Wang J, and Law AV. A formal mentorship program for faculty development. *American Journal of Pharmaceutical Education*, 2014;78(5):100. [Original research]

Vivian E, Ikem P, Shiyabola O, Tolson Y, and **Le Jennifer**. Health needs and neighborhood concerns of low income households vulnerable to food insecurity. *Public Health* 2014; 128(8):743–745. [Original clinical research]

**Le Jennifer**, Dam Q, Schweizer M, Thienphrapa W, Nizet V, and Sakoulas G. Effects of vancomycin versus nafcillin in enhancing killing of methicillin-susceptible *Staphylococcus aureus* bacteremia by human cathelicidin LL-37. *European Journal of Clinical Microbiology & Infectious* 2016;35(9):1441-7. [Original clinical research]

**Le Jennifer**, Ny P, Capparelli EVC, Lane JR, Ngu B, Muus R, Romanowski G, Vo T, and Bradley JS. Pharmacodynamic characteristics of nephrotoxicity associated with vancomycin use in children. *J Pediatric Infect Dis Soc* 2015;4(4):e109-16. [Original clinical research]

Wing DA, Rumney PJ, Hindra SS, Guzman L, **Le Jennifer**, and Nageotte MP. Pilot investigation to evaluate compliance and tolerability of cranberry capsules in pregnancy for the prevention of asymptomatic bacteriuria in pregnancy. *J Altern Complement Med* 2015;21(11):700-6. [Original clinical research]

Ghonimat IM, Nazer LH, Aqel F, Mohammed MK, Hawari FI, and **Le Jennifer**. Effect of nebulized colistin on the ventilator circuit: a prospective pilot case-control study from a single cancer center. *Mediterr J Hematol Infect Dis* 2015;7(1):e2015032. [Original clinical research]

Nazer LH, Rihani S, Hawari FI, and **Le Jennifer**. High-dose colistin for microbiologically documented serious respiratory infections associated with carbapenem-resistant *Acinetobacter baumannii* in critically ill cancer patients: a retrospective cohort study. *Infect Dis (Lond)* 2015;47(11):755-60. [Original clinical research]

**Le Jennifer**, Capparelli EV, Wahid U, Wu YS, Romanowski GL, Tran TM, Nguyen A, Bradley JS. Bayesian estimation of vancomycin



pharmacokinetics in obese children: matched case-control study. *Clin Ther* 2015 Jun 1;37(6):1340-51. [Original clinical research]

Abdel Hadi O, Al Omar S, Nazer LH, Mubarak S, and **Le Jennifer**. Vancomycin pharmacokinetics and predicted dosage requirements in pediatric cancer patients. *J Oncol Pharm Pract* 2016;22(3):448-53. [Original clinical research]

Cannavino CR, Mendes RE, Sader HS, Farrell DJ, Critchley IA, Biek D, **Le Jennifer**, et al. Evolution of ceftaroline-resistant MRSA in a child with cystic fibrosis following repeated antibiotic exposure. *Pediatr Infect Dis J* 2016;35(7):813-5. [Case report]

Kinney A, Bui Q, Hodding J, and **Le Jennifer**. Pharmacy dashboard: an innovative process for pharmacy workload and productivity in real-time. *Hospital Pharmacy* 2017;52(3):198-206. [Original clinical research]

Bethencourt DM, **Le Jennifer**, Rodriguez G, Kalayjian RW, and Thomas GS. Minimally-invasive aortic valve replacement via right anterior mini-thoracotomy and central aortic cannulation: a 13-year experience. *Innovations (Phila)* 2017;12(2):87-94 [Original clinical research]

Tran T, Khatrar S, Vu TT, Potter M, Hodding J, Kuo GM, and **Le Jennifer**. Impact of pharmacist discharge counseling on hospital readmission and emergency department visit. *Journal of Hospital Administration* 2017;6(2):68-73. [Original clinical research]

Avedissian S, Bradley JS, Zhang D, Tran TM, Nguyen A, Bradley E, and **Le Jennifer**. Augmented renal clearance using population-based pharmacokinetic modeling in critically-ill pediatric patients *Pediatric Critical Care Medicine* 2017;18(9):e388-e394. [Original clinical research]

**Le Jennifer**, Dam Q, Tran TM, Nguyen A, Adler-Shohet FC, Kim S, Schmidt K, Lieberman JM, and Bradley JS. Complications associated with *Staphylococcus aureus* bacteremia in children over a 25-year period. *Epidemiology & Infection* 2017;145(12):2631-2639 [Original clinical research]

**Le Jennifer**, Capparelli EV, Hingtgen S, Scochko S, Black N, Jones RN, Lim Meerana, and Bradley JS. Population pharmacokinetic profile and pharmacodynamic target attainment for Staphylococcal pneumonia in children with cystic fibrosis following single-dose ceftaroline fosamil. *Pediatric Pulmonology* 2017;52(11):1424-1434. [Original clinical research]

**Le Jennifer**, Turner N, Deshpande LM, Davis AP, Castanheira M. Case Report of Transient *mcr-1*-harboring *E. coli* with concurrent *S. aureus* bacteremia in Long Beach, California. *Diagnostic Microbiology and Infectious Disease* 2017;89(4):303-304. [Case report]

Sauberan JB, Choi B, Paradyse AR, and **Le Jennifer**. Quality and Clinical Outcomes Associated with a Gentamicin Use System Change for Managing Chorioamnionitis. *Journal of Med Syst.* 2017;41(12):202. [Original clinical research]

**Le Jennifer**, Poindexter B, Sullivan JE, Laughon M, Delmore P, Blackford M, Yogev R, et al. Comparative Analysis of Ampicillin Plasma and Dried Blood Spot Pharmacokinetics in Neonates. *Therapeutic Drug Monitoring* 2018;40(1):103-108. [Original clinical research]

Sader HS, Mendes RE, **Le Jennifer**, Denys G, Flamm RK, and Jones RN. Antimicrobial Susceptibility of *Streptococcus pneumoniae* from North America, Europe, Latin America, and the Asia-Pacific Region: Results From

20 Years of the SENTRY Antimicrobial Surveillance Program (1997-2016). *Open Forum Infect Dis.* 2019;6(Suppl 1):S14-S23. [Original research]

Nazer LH and **Le Jennifer**. Cost-effective analysis of low- versus high-dose colistin in the treatment of multi-drug resistant pneumonia in Saudi Arabia. *Int J Clin Pharm* 2019;41(1):1-2. PubMed PMID: 30661216. [Letter to editor]

Jimenez A, Tran TM, Le B and **Le Jennifer**. Comparative Cross-Sectional Pharmacovigilance Study of Medication Errors in Children and Adults in Community-Based Hospitals. *J Pediatrics Child Health* 2020;2(1):1-12. [Original research]

Avedissian SN, Rhodes NJ, Kim Y, Bradley J, Valdez JL, and **Le Jennifer**. Augmented renal clearance of aminoglycosides using population-based pharmacokinetic modelling with Bayesian estimation in the paediatric ICU. *J Antimicrob Chemother.* 2020;75(1):162-169. doi: 10.1093/jac/dkz408. PubMed PMID: 31648297. [Original clinical research]

Rybak MJ, **Le Jennifer**, Lodise TP, Levine DP, Bradley JS, Liu C, et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant *Staphylococcus aureus* infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. *Am J Health Syst Pharm* 2020 ;77(11) :835-864. doi: 10.1093/ajhp/zxaa036. PubMed PMID: 32191793. [National consensus guideline by four national professional societies]

Ericson JE, Hornik CP, Greenberg RG, Clark RH, Tremoulet AH, **Le Jennifer**, et al. Paradoxical Antibiotic Effect of Ampicillin: Use of a Population Pharmacokinetic Model to Evaluate a Clinical Correlate of the Eagle Effect in Infants with Bacteremia. *Pediatr Infect Dis J* 2020;39(8):725-729. PMID: 32235247 [Original clinical research]

Rybak MJ, **Le Jennifer**, Lodise TP, Levine DP, Bradley JS, Liu C, et al. Executive Summary: Therapeutic Monitoring of Vancomycin for Serious Methicillin-Resistant *Staphylococcus aureus* Infections: A Revised Consensus Guideline and Review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. *Pharmacotherapy* 2020;40(4):363-367. doi: 10.1002/phar.2376. PubMed PMID: 32227354. [Executive summary of national consensus guideline by four national professional societies]

Tran TT, Pham B, Vo T, Hodding, J and **Le Jennifer**. Innovative Approach to the Medication Verification Process: Role of Pharmacists in the Minimization of Confirmation Bias. *International Journal of Healthcare* 2020;6(2):62-68. doi: 10.5430/ijh.v6n2p62 [Original clinical research]

Rybak MJ, **Le Jennifer**, Lodise TP, Levine DP, Bradley JS, Liu C, et al. Executive Summary: Therapeutic Monitoring of Vancomycin for Serious Methicillin-Resistant *Staphylococcus aureus* Infections: A Revised Consensus Guideline and Review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. *J Pediatric Infect Dis Soc* 2020;9(3):281-284. doi: 10.1093/jpids/piaa057. PubMed PMID: 32659787. [Executive summary of national consensus guideline by four national professional societies]

Rybak MJ, **Le Jennifer**, Lodise TP, Levine DP, Bradley JS, Liu C, et al. Therapeutic Monitoring of Vancomycin for Serious Methicillin-Resistant Staphylococcus aureus Infections: A Revised Consensus Guideline and Review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. *Clin Infect Dis* 2020 Jul 13:ciaa303. doi: 10.1093/cid/ciaa303. PubMed PMID: 32658968. [Executive summary of national consensus guideline by four national professional societies]

Avedissian SN, Rohani R, Bradley J, **Le Jennifer\*** and Rhodes NJ. Optimizing aminoglycoside dosing regimens for critically-ill pediatric patients with augmented renal clearance: a convergence of parametric and non-parametric population approaches. *Antimicrob Agents Chemother* 2021 Feb 1: AAC.02629-20. doi: 10.1128/AAC.02629-20. PMID: 33526481. [Original clinical research]

AbuSara AK, Abdelrahman D, Habash K, Al-Shaer MH, Faldasz J, **Le Jennifer**, and Nazer LH. Vancomycin therapeutic monitoring by Bayesian-derived area under the curve versus measured trough concentrations in critically-ill cancer patients [Submitted to Peer-Review Journal]

**Le Jennifer**, Greenberg RG, Benjamin Jr DK, Yoo Y, et al on behalf of the Administrative Core Committee of the Best Pharmaceuticals for Children Act – Pediatric Trials Network. Prolonged Post-Discontinuation Antibiotic Exposure in Very Low Birth Weight Neonates at Risk for Early-Onset Sepsis [Original clinical research] [Submitted to Peer-Review Journal]

**Le Jennifer**, Greenberg RG, Benjamin Jr DK, Yoo Y, et al on behalf of the Administrative Core Committee of the Best Pharmaceuticals for Children Act – Pediatric Trials Network. Post-Discontinuation Antibiotic Exposure in Neonatal Late-Onset Sepsis [Original clinical research] [Manuscript in Preparation]

**Le Jennifer**, Dam Q, Tran TM, Tung NP, Huynh DL, Hulten KG, Harrison CJ, Kaplan SL, and Bradley JS. Pharmacodynamic Antibiotic Dosing in Pediatric Community-Acquired Pneumococcal Pneumonia in an Era of 13-Valent Pneumococcal Conjugate Vaccine [Original clinical research] [Manuscript in Preparation]

Han J, Sauberan J, Tran T, Tran L, Michalik D and **Le Jennifer**. Implementation of Vancomycin Therapeutic Monitoring Guideline: Focus on Bayesian Estimation Tools for Neonates and Pediatrics [Review article] [Manuscript in Preparation]

## ARTICLES

**Le Jennifer** and Tsourounis C. Implanon: a critical review. *Annals of Pharmacotherapy* 2001;35:329-336. [Review article]

**Le Jennifer**, Briggs G, McKeown A, Bustillo J. Urinary tract infections during pregnancy. *Annals of Pharmacotherapy* 2004;38:1692-1701. [Review article]

**Le Jennifer** and Lipsky M. Management of bacterial rhinosinusitis. *American Journal of Managed Care* 2004;4:S3-11. [Review article]

**Le Jennifer** and Lipsky M. Therapeutic management of bronchitis. *American Journal of Managed Care* 2005;5:S3-10. [Review article]

**Le Jennifer** and Lieberman JM. Management of community-associated methicillin-resistant *Staphylococcus aureus* infections in children. *Pharmacotherapy* 2006;26:1758-1770. [Review article]

**Le Jennifer**, Dodds-Ashley E, Neuhauser MM, Brown J, Gentry C, Klepser ME, et al. Insights from the Society of Infectious Diseases Pharmacist: Consensus Review of Aerosolized Antimicrobial Agents Using Evidence-based Pharmacotherapy. *Pharmacotherapy* 2010;30:562-584. [Major article in form of evidenced-based consensus statement by the Society of Infectious Diseases Pharmacists]

**Le Jennifer** and Schiller D. Aerosolized delivery of antifungal agents. *Current Fungal Infection Reports* 2010;4:96-102. [Review article]

Jahng M and **Le Jennifer**. Daptomycin for treatment of complicated skin and skin structure infections. *Healthy Aging & Clinical Care in the Elderly* 2012;4:13–25. [Invited Review Article; I invited Dr. Jahng (former pharmacy resident) to serve as first author to support his scholarly career development]

Natale S, Bradley JS, Nguyen WH, Tran TM, Ny P, La K, Vivian EM, and **Le Jennifer**. Pediatric obesity: pharmacokinetic alterations and effects on antimicrobial dosing. *Pharmacotherapy* 2017 Mar;37(3):361-378. [Review article]

**Le Jennifer**, Bradley JS. Optimizing Antibiotic Drug Therapy in Pediatrics: Current State and Future Needs. *J Clin Pharmacol* 2018;58 Suppl 10:S108-S122. [Review article]

Mashni O, Nazer L, and **Le Jennifer**. Critical Review of Double-Carbapenem Therapy for the Treatment of Carbapenemase-Producing *Klebsiella pneumoniae*. *Ann Pharmacotherapy* 2019;53(1):70-81. [Review article]

Nazer LH, **Le Jennifer**. Cost-effective Analysis of Low- versus High-dose Colistin in the Treatment of Multi-drug Resistant Pneumonia in Saudi Arabia. *Int J Clin Pharm.* 2019;41(1):1-2 [Letter to Editor]

Zeitlinger M, Koch BCP, Bruggemann R, Cock PD, Felton T, Hites M, **Le Jennifer** et al (listed in *alphabetical order* except for first and last authors). Pharmacokinetics/Pharmacodynamics of Antiviral Agents Used to Treat SARS-CoV-2 and Their Potential Interaction with Drugs and Other Supportive Measures: A Comprehensive Review by the PK/PD of Anti-Infectives Study Group of the European Society of Antimicrobial Agents. *Clin Pharmacokinet* 2020. <https://doi.org/10.1007/s40262-020-00924-9> [Review article]

Simonian JS, Varanasi S, Richards GJ, Nguyen AV, Diaz-Fong JP, and **Le Jennifer**. Critical Review of Medical Cannabis in Pediatrics Beyond Epilepsy, Part I: Background. *Pediatric Medicine* 2020; in press [Invited review article]

Simonian JS, Varanasi S, Nguyen AV, Diaz-Fong JP, and **Le Jennifer**. Critical Review of Medical Cannabis in Pediatrics Beyond Epilepsy, Part III: Chemotherapy-Induced Nausea and Vomiting and Inflammatory Bowel Disease. *Pediatric Medicine* 2020; in press [Invited review article]

Lee HS, Plechot K, Gohil S and **Le Jennifer**. *Clostridium difficile*: Diagnosis and the Consequence of Over Diagnosis. *Infectious Diseases and Therapy* 2020; in press [Invited review article]

Jones JF, Legaspi J, Chen E, Lee KC and **Le Jennifer**. Emerging Viral and Bacterial Infections: Within an Era of Opioid Epidemic. *Infectious Diseases and Therapy* 2020; pending publication [Invited review article]  
Avedissian SN, Rhodes N, Shaffer C, Tran L, Bradley JS, and **Le Jennifer**. Antimicrobial Prescribing for Serious Infections Caused by Methicillin-Resistant *Staphylococcus aureus* in Pediatrics: An Expert Review. *Expert Review of Anti-infective Therapy* 2021; pending publication [Invited review article]

## CHAPTERS

**Le Jennifer**. Pharmacokinetics. In: *The Merck Manual of Diagnosis and Therapy*. 19<sup>th</sup> edition. Whitehouse Station, NJ: Merck Sharp & Dohme Corp, 2012. [Invited author]

**Le Jennifer**. Administration and kinetics of drugs. In: *The Merck Manual Home Health Handbook*. Whitehouse Station, NJ: Merck Sharp & Dohme Corp, 2012. [Invited author]

**Le Jennifer**. Upper respiratory tract infections: acute otitis media, rhinosinusitis and pharyngitis. In: *Pediatric Pharmacotherapy*. Lenexa, Kansas: American College of Clinical Pharmacy, 2013 (Chapter 36, 528-545). [Invited author and editorial board member]

**Le Jennifer**. Kawasaki disease. In: *Pediatric Pharmacotherapy*. Editors: Nahata M, Lenexa, Kansas: American College of Clinical Pharmacy, 2013 (Chapter 45, 708-717). [Invited author and editorial board member]

**Le Jennifer**, Jahng M. Skin and Skin Structure Infections. Ambulatory Care Self-Assessment Program (ACSAP), Book 2: Infection Primary Care; July 15, 2013. [Invited author]

**Le Jennifer**. Do I dose medications the same for the obese child as a normal weight child? In: *Curbside Consultation in Pediatric Obesity: 49 clinical questions*. Thorofare, New Jersey: Slack, Inc., April 2014. [Invited author]

La K, **Le Jennifer**. What drugs are available to treat obesity in children? In: *Curbside Consultation in Pediatric Obesity: 49 clinical questions*. Thorofare, New Jersey: Slack, Inc., April 2014. [Invited author]

**Le Jennifer**. Kawasaki disease. In: *Pediatric Pharmacotherapy Self-Assessment*. Bethesda, Maryland: American Society of Health-Systems Pharmacists Special Publishing, 2014 (Chapter 9) [Invited author]

**Le Jennifer**. Skin and skin structure infection. In: *Pediatric Pharmacotherapy Self-Assessment*. Bethesda, Maryland: American Society of Health-Systems Pharmacists Special Publishing, 2014 (Chapter 9) [Invited author]

**Le Jennifer**, Chan D. Neonatal sepsis. In: *Electronic Supplement to Pediatric Pharmacotherapy Self-Assessment*. Bethesda, Maryland: American Society of Health-Systems Pharmacists Special Publishing, 2014 (Chapter 9) [Invited author]

**Le Jennifer**, Chan D. Osteomyelitis. In: *Electronic Supplement to Pediatric Pharmacotherapy Self-Assessment*. Bethesda, Maryland: American Society of Health-Systems Pharmacists Special Publishing, 2014 (Chapter 9). [Invited author]

Chan D and **Le Jennifer**. Acute otitis media. In: *Pediatric Pharmacotherapy Self-Assessment*. Bethesda, Maryland: American Society of Health-Systems Pharmacists Special Publishing, 2014 (Chapter 9). [Invited author]



Chan D and **Le Jennifer**. Pneumonia. In: *Pediatric Pharmacotherapy Self-Assessment*. Bethesda, Maryland: American Society of Health-Systems Pharmacists Special Publishing, 2014 (Chapter 9). [Invited author]

**Le Jennifer** and Bradley JS. Pharmacodynamic considerations and special populations – pediatrics. In: *Antibiotic Pharmacodynamics*. New York: Springer Science & Business Media LLC, 2014. [Invited author]

**Le Jennifer**. Pharmacokinetics. In: *The Merck Manual of Diagnosis and Therapy*. Whitehouse Station, NJ: Merck Sharp & Dohme Corp, 2014. [Invited author]

**Le Jennifer**. Administration and kinetics of drugs. In: *The Merck Manual Home Health Handbook*. Whitehouse Station, NJ: Merck Sharp & Dohme Corp, 2014. [Invited author]

**Le Jennifer** and Bradley JS. Pharmacodynamic considerations and special populations – pediatrics. In: *Antibiotic Pharmacodynamics*. New York: Springer Science & Business Media LLC, 2016, pp 561-597. [Invited author]

Finley PR, **Le Jennifer** and Lee KC. Antidepressants. In: *Applied Pharmacokinetic and Pharmacodynamics of Psychopharmacological Agents*. Switzerland: Springer International Publishing Switzerland, 2016. [Invited author]

**Le Jennifer**. Pharmacokinetics. In: *The Merck Manual of Diagnosis and Therapy*. Whitehouse Station, NJ: Merck Sharp & Dohme Corp, 2016. [Invited author]

**Le Jennifer**. Administration and kinetics of drugs. In: *The Merck Manual Home Health Handbook*. Whitehouse Station, NJ: Merck Sharp & Dohme Corp, 2016. [Invited author]

**Le Jennifer**. Upper respiratory tract infections: acute otitis media, rhinosinusitis and pharyngitis. In: *Pediatric Pharmacotherapy*. Lenexa, Kansas: American College of Clinical Pharmacy, 2017 in progress. [Invited author and editorial board member]

**Le Jennifer**. Kawasaki disease. In: *Pediatric Pharmacotherapy*. Editors: Nahata M, Lenexa, Kansas: American College of Clinical Pharmacy, 2017. [Invited author and editorial board member]

Lee H and **Le Jennifer**. Urinary tract infections. In: *ACCP's Pharmacotherapy Self-Assessment Programs (PSAP) 2016-2018 Series: Infectious Diseases*, 2017. [Invited author]

**Le Jennifer**. Pharmacokinetics. In: *The Merck Manual of Diagnosis and Therapy*. Whitehouse Station, NJ: Merck Sharp & Dohme Corp, 2017. [Invited author]

**Le Jennifer** and Dam Q. Skin and soft tissue infections. In: McGraw Hill and Scott Sutton Naplex Review Guide. New York, NY: McGraw-Hill, 2017, in press. [Invited author]

**Le Jennifer**. Kawasaki disease. In: *Pediatric Pharmacotherapy*. Editors: Nahata M, Lenexa, Kansas: American College of Clinical Pharmacy, 2018. [Invited author]

**Le Jennifer**. Upper respiratory tract infections: acute otitis media, rhinosinusitis and pharyngitis. In: *Pediatric Pharmacotherapy*. Lenexa, Kansas: American College of Clinical Pharmacy, 2019. [Invited author]

**Le Jennifer**. Pharmacokinetics. In: *The Merck Manual of Diagnosis and Therapy*. Whitehouse Station, NJ: Merck Sharp & Dohme Corp, 2019. [Invited author]

**Le Jennifer.** Pharmacokinetics. In: *The Merck Manual of Diagnosis and Therapy*. Whitehouse Station, NJ: Merck Sharp & Dohme Corp, 2019. [Invited author]

**Le Jennifer** and Jones J. Skin and soft tissue infections. In: McGraw Hill and Scott Sutton Naplex Review Guide, 4th edition. New York, NY: McGraw-Hill, 2020. [Invited author]

**Le Jennifer.** Kawasaki disease. In: *Pediatric Pharmacotherapy*. Editors: Nahata M, Lenexa, Kansas: American College of Clinical Pharmacy, 2020. [Invited author and editorial board member]

**Le Jennifer.** Upper respiratory tract infections: acute otitis media, rhinosinusitis and pharyngitis. In: *Pediatric Pharmacotherapy*. Lenexa, Kansas: American College of Clinical Pharmacy, 2020. [Invited author and editorial board member]

**Le Jennifer** and Bradley JS. Macrolides, Clindamycin, and Oxazolidones (Chapter 32). In: *Neonatal & Pediatric Pharmacology: Therapeutic Principles in Practice*. Editors: Yaffe SJ & Aranda JV. Philadelphia, PA: Lippincott Williams & Wilkins, 2020. [Invited author]

**Le Jennifer.** Pharmacokinetics. In: *The Merck Manual of Diagnosis and Therapy*. Whitehouse Station, NJ: Merck Sharp & Dohme Corp, 2020. [Invited author]

**Le Jennifer.** *The Merck Manual of Diagnosis and Therapy*. Whitehouse Station, NJ: Merck Sharp & Dohme Corp, 2020. [Facilitator for translation into Vietnamese <https://www.msdmanuals.com/vi/chuyen-gia>]

## PROCEEDINGS

**Le Jennifer,** Nguyen T, Law AV, and Hodding J. Retrospective analysis of adverse drug reactions in hospitalized pediatrics over 10-year period. *Pharmacotherapy* 2005;25(10):1431.

Wang J, **Le Jennifer,** Murray W, McGory R. Longitudinal development of pharmacokinetics in the pharmacy curriculum. *American Journal of Pharmaceutical Education* 2006; 70 (3) Article 65; page 14.

**Le Jennifer,** Kim J, Taing S, Kildoo CW. Evaluation of empiric antibiotic use in the treatment (of healthcare-associated pneumonia in hospitalized patients. *American Journal of Health-System Pharmacy*; 2007;63(20):1901-2014

The FOD working committee (Betageri G, Hess K, Jackevicius C, Law AV, **Le Jennifer,** Min D, Murray W and Pham D - listed in alphabetical order). A model to address faculty development and enrichment: The Faculty Orientation and Development Committee. *American Journal of Pharmaceutical Education* 2009; 73 (4) Article 57; page 96.

**Le Jennifer,** Hernandez E, Jahng M, McKamy S. Nephrotoxicity associated with high vancomycin troughs in children. *Pharmacotherapy* 2009;29(10):1273.

**Le Jennifer,** Jones RN, Castanheira M, Srisupha-olarn W and Burgess DS. *In vitro* activity of carbapenems alone and in combination with amikacin against extended-spectrum beta-lactamase (ESBL)-producing bacteria with reduced carbapenem susceptibility. *Pharmacotherapy* 2009;29(10):1273.

Wang MW, Padilla L, Song T, Tran V, Tran T, and **Le Jennifer**. Evaluation of risk factors associated with invasive candidiasis in critically ill infants. *Pharmacotherapy* 2009;29(10):1273.

Nazer L, Sheikha L, Anabtawi N and **Le Jennifer**. Predictors of Augmented Renal Clearance in Critically-Ill Patients with Cancer. Poster presentation at Society of Critical Care Medicine. *Critical Care Medicine* 2019;47:70

**Le Jennifer**, Le K, Nazareth S, and Seto S. Discrepancies in medication order entry within a dual- computer system. Co-presenter, Poster presentation at ASHP Midyear Meeting, December 2001 in Las Vegas, NV.

**Le Jennifer**, Adler-Shohet F, Nguyen C and Lieberman J. Nephrotoxicity Associated with Conventional Amphotericin B in Neonates. Presenter, Poster presentation at the 43rd Annual Meeting of the Infectious Diseases Society of America, October 2005 in San Francisco, CA.

**Le Jennifer**, Nguyen T, Law AV, and Hodding J. Retrospective analysis of adverse drug reactions in hospitalized pediatrics over 10-year period. Presenter, Poster presentation at the Annual Meeting of the American College of Clinical Pharmacy, October 2005 in San Francisco, CA.

Wang J, **Le Jennifer**, Murray W, McGory R. Longitudinal development of pharmacokinetics in the pharmacy curriculum. Co-presenter, Poster presentation at the Annual Meeting of American Association of Colleges of Pharmacy, July 2006 in San Diego, CA.

**Le Jennifer**, Nguyen T, Okamoto M, Lieberman JM. Impact of empiric antibiotic use on the development of infections caused by extended-spectrum beta-lactamase bacterial pathogens in the neonatal intensive care unit. Presenter, Poster presentation at the 46<sup>th</sup> Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, September 2006 in San Francisco, CA.

**Le Jennifer**, Adler-Shohet FC, Quist R, Lieberman JM. Disseminated candidiasis in neonates. Presenter, Poster presentation at the 46<sup>th</sup> Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, September 2006 in San Francisco, CA.

**Le Jennifer**, Kim J, Taing S, Kildoo CW. Evaluation of empiric antibiotic use in the treatment of healthcare-associated pneumonia in hospitalized patients. Co-presenter, Poster presentation at the Annual Meeting of American Society of Health-System Pharmacists, December 2006 in Anaheim, CA; and encore presentation at the Spring Forum of the American College of Clinical Pharmacy, April 2007 in Memphis, TN.

**Le Jennifer**, SanAgustin M, Hernandez E, Adler-Shohet FC. Complications associated with outpatient parenteral antibiotic therapy in children. Co-presenter, Poster presentation at the Annual Meeting of Infectious Diseases Society of America, October 2007 in San Diego, CA and and encore presentation at the Annual Long Beach Research Symposium, November 2008 in Long Beach, CA.

The FOD working committee (Betageri G, Hess K, Jackevicius C, Law AV, **Le Jennifer**, Min D, Murray W and Pham D - listed in alphabetical order). A model to address faculty development and enrichment: The Faculty Orientation and Development Committee. Poster presentation at the



Annual Meeting of American Association of Colleges of Pharmacy, July 2009 in Boston, MA.

**Le Jennifer**, Castanheira M, Chinn R, Jones RN. Clinical outcomes of infections caused by extended-spectrum  $\beta$ -lactamase (ESBL)-producing bacteria with reduced carbapenem susceptibility. Presenter, Poster presentation at the Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, September 2009 in San Francisco, CA.

Castanheira M, Woosley LN, Brady KM, Jones RN, and **Le Jennifer**. High prevalence of CTX-M-producing isolates and emergence of KPC-encoding genes in the western United States (USA). Poster presentation at the Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, September 2009 in San Francisco, CA.

**Le Jennifer**, Hernandez E, Jahng M, McKamy S. Nephrotoxicity associated with high vancomycin troughs in children. Co-presenter, Poster presentation at the Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, September 2009 in San Francisco, CA and encore presentation at the Annual Meeting of the American College of Clinical Pharmacy, October 2009 in Anaheim, CA

**Le Jennifer**, Jones RN, Castanheira M, Srisupha-olarn W and Burgess DS. *In vitro* activity of carbapenems alone and in combination with amikacin against extended-spectrum beta-lactamase (ESBL)-producing bacteria with reduced carbapenem susceptibility. Presenter, Poster presentation at the Annual Meeting of the American College of Clinical Pharmacy, October 2009 in Anaheim, CA.

Wang MW, Padilla L, Song T, Tran V, Tran T, and **Le Jennifer**. Evaluation of risk factors associated with invasive candidiasis in critically ill infants. Co-presenter, Poster presentation at the Annual Meeting of the American College of Clinical Pharmacy, October 2009 in Anaheim, CA.

Burgess DS, McKee B, Srisupha-olarn W, and **Le Jennifer**. In vitro Activity of Carbapenems Alone and in Combination with Amikacin against KPC-producing *K. pneumoniae*. Poster presentation at the Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, September 2010 in Boston, MA.

**Le Jennifer**, Adler-Shohet FC, Bradley J, Tran T and Lieberman JM. Complications associated with *Staphylococcus aureus* bacteremia in children. Presenter, Poster presentation at the Annual Meeting of Infectious Diseases Society of America, October 2010 in Vancouver, Canada.

**Le Jennifer**, Bradley JS, Murray W, Romanowski GL, Nguyen N, Cho S, Natale S, Tran T, Bui I and Capparelli EV. Vancomycin Dosing in Children by Area-Under-the Curve (AUC). Presenter, Oral presentation at the Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, September 2011 in Chicago, IL.

**Le Jennifer**, Vaida F, Nguyen E, Adler-Shohet FC, Kim J, Vo T, and Capparelli EV. Population-based Pharmacokinetic Modeling of Vancomycin in Children with Renal Impairment. Presenter, Poster presentation at ID Week—Annual Meeting of Infectious Diseases Society of America and Pediatric Infectious Disease Society, October 2012 in San Diego, CA.

Ngu B, Capparelli EV, Bradley JS, Murray B, Romanowski GL, and **Le Jennifer**. Accuracy of Vancomycin Monitoring in Children. Presenter, Poster presentation at ID Week—Annual Meeting of Infectious Diseases Society of

America and Pediatric Infectious Disease Society, October 2012 in San Diego, CA.

Abdel Hadi O, Nazer LH, Al Omar S, Mubarak S, Capparelli E, and **Le Jennifer**. Vancomycin Pharmacokinetics and Dosage Requirements in Pediatric Cancer Patients. Fourth Regional Congress of Cancer and Blood Disorders of Childhood, Jordan Society of Oncology Pediatrics, November 2012 in Amman, Jordan (**Best Poster Award**).

Ghonimat I, Nazer LH, Aqel F, **Le Jennifer**. Ventilator Circuit Obstruction Associated with Aerosolized Colistin. SCCM Annual Meeting, 2013 in San Juan, PR.

Ola A, Nazer L, **Le Jennifer**. Vancomycin Pharmacokinetics and Dosage Requirements in Pediatric Cancer Patients. Platform presentation at the Virtual Poster Symposium of the American College of Clinical Pharmacy, May 2013. [Encore]

Ghonimat I, Nazer L, Aqel E, Hawari F, and **Le Jennifer**. Effect of Aerosolized Colistin on the Ventilator Circuit: A Pilot Case-control Study. Platform presentation at the Virtual Poster Symposium of the American College of Clinical Pharmacy, May 2013 (Finalist for the Best Resident and Fellow Poster Competition). [Encore]

Bradley J, **Le Jennifer**, Ramachandra Rao S, Rossi S, Hingtgen S, Farrell M, Capparelli EV. Colistin (COL) Single Dose Pediatric Pharmacokinetics and Renal Safety. Presenter, poster presentation at the Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, September 2013 in Denver, CO.

Ny P, Capparelli EV, Bradley JS, Lane J, Ngu B, Muus R, Romanowski R, Vo T, and **Le Jennifer**. Characteristics of Nephrotoxicity Associated with Vancomycin Use in Children. Presenter, poster presentation at ID Week—Annual Meeting of Infectious Diseases Society of America and Pediatric Infectious Disease Society, October 2013 in San Francisco, CA.

Hornik CP, Benjamin DK, Clark RH, Capparelli EV, **Le Jennifer**, Tremoulet A, Cohen-Wolkowicz and Smith BP for the Best Pharmaceuticals for Children Act – Pediatric Trials Network. Ampicillin Exposure and Odds of Seizures in a Large Cohort of Hospitalized Neonates. Poster at the Annual Meeting of the Pediatric Academic Societies, May 2014 in Vancouver, Canada.

Adler-Shohet FC, Kleis K, Singh J, Schlechter J, Trent E, Osborne S, Davis AP, Frey-Perkis E, Arrieta A and **Le Jennifer**. Treatment and Outcome of Culture-negative Osteomyelitis in Children. Poster presentation at ID Week—Annual Meeting of Infectious Diseases Society of America and Pediatric Infectious Disease Society, October 2014 in Philadelphia, PA.

Nazer LH, Rihani S, Hawari FI, and **Le Jennifer**. Microbiological Clearance and Nephrotoxicity Associated with High-dose Colistimethate Sodium (1720). Poster presentation accepted at the 43rd Critical Care Congress of the Society of Critical Care Medicine, January 2015 in Phoenix, AZ.

Nguyen WH, Bradley JS, Capparelli EV, Wu YS, Tran TM, Romanowski GL, Adler-Shohet FC, and **Le Jennifer**. Optimal Weight-based Vancomycin Dosing in Obese Children Using Bayesian Estimation. Poster presentation at the University of California San Diego Pediatric Symposium, April 2015 in La Jolla, CA.

Tran T, Saijal K, Vu Tiffany, Potter M, Hodding J, Kuo GM, and **Le Jennifer**. Impact of Pharmacist Discharge Counseling on Hospital Readmission and

Emergency Department Visit. Poster presentation at California Health Systems Pharmacist, October 2015 in San Diego, CA.

Avedissian S, Zhang D, Bradley JS, Nazer L, Nguyen A, Tran T, Bradley E, and **Le Jennifer**. Augmented Renal Clearance Using Vancomycin Population-Based Pharmacokinetic Modeling With Bayesian Estimation in Critically-ill Pediatric Patients. Poster presentation at ID Week—Annual Meeting of Infectious Diseases Society of America and Pediatric Infectious Disease Society, October 2016 in New Orleans, LA.

Singh S, Lee K, Humber D, Lorentz S, Ma J, Colbert J, Painter N, Fricovsky E, Atayee R, and Le Jennifer. An Innovative Process for Systematic Review of Experiential Courses. Poster American Association of Colleges of Pharmacy, June 2017 in Nashville, TN.

Tran TT, Pham B, Vo T, Hodding, J and **Le Jennifer**. Innovative Approach to the Medication Verification Process: Role of Pharmacists in Minimizing of Confirmation Bias. Poster presentation at CSHP Seminar 2017, October 2017 in Las Vegas, NV.

Avedissian S, Rhodes NJ, Nazer L, Kim Y, Valdez J, Bradley JS, and **Le Jennifer**. Augmented Renal Clearance Using Aminoglycoside Population-Based Pharmacokinetic Modeling With Bayesian Estimation in Children in the Pediatric Intensive Care Unit. Poster presentation at ID Week—Annual Meeting of Infectious Diseases Society of America and Pediatric Infectious Disease Society, October 2018 in San Francisco, CA.

Sader HS, Mendes RE, **Le Jennifer**, Denys G, Flamm RK, and Jones RN. Antimicrobial Susceptibility of Streptococcus Pneumonia From North America, Europe, Asia, and Latin America: Results from 20 Years of the Sentry Antimicrobial Surveillance Program (1997-2016). Poster presentation at ASM Microbe, June 2018, Atlanta, GA.

Nazer L, Sheikha L, Anabtawi N and **Le Jennifer**. Predictors of Augmented Renal Clearance in Critically-Ill Patients with Cancer. Poster presentation at Society of Critical Care Medicine. Critical Care Congress, February 2019 in San Diego, CA.

Rhodes NJ, Avedissian SN, Hadid A, Bradley JS and **Le Jennifer**. Effect of augmented renal clearance on the extended-interval dosing of aminoglycosides in critically ill paediatric patients. Poster presentation at the 30<sup>th</sup> European Congress of Clinical Microbiology and Infectious Diseases, April 2020 in Paris, France. Canceled due to COVID-19

**Le Jennifer**, Greenberg RG, Yoo Y, Clark RH, Benjamin D, Zimmerman K, Cohen-Wolkowicz M, and Wade K. Prolonged Antibiotic Exposure After Discontinuing Antibiotics in Premature Neonates Receiving Empiric Treatment for Early-Onset Sepsis Exposure-Driven Antibiotic Treatment Duration for Premature Neonates with Suspected Early-Onset Sepsis. Invited Virtual Oral Presentation at the Pediatric Academic Society, August 2020.

## WORKS

**Le Jennifer**. Patient education pamphlet and a drug-herb interaction table of commonly-used herbal medicines. Long Beach Memorial Medical Center, 2001.

**Le Jennifer.** Aranesp monograph for pharmacy & therapeutics committee. Peer-reviewed by Susan Vancampen, Neepa Rai; Approved by the Pharmacy & Therapeutics Committee, 2002.

**Le Jennifer.** Revision of adult intravenous digoxin guideline for pharmacist-regulated therapies. Peer-reviewed by Ambrose P, Kildoo C, Rai N, Safani M, Tobias S, Van Campen S, Warren V; Approved by: EP/Pacer Subcommittee of Department of Cardiology, October 30, 2003 and Pharmacy & Therapeutics Committee, November 18, 2003. [Clinical practice guideline]

**Le Jennifer,** Wachtfogel M, Nazareth S, Chu Kathlynn and Tran K. Chemotherapy monitoring form. Long Beach Memorial Medical Center, 2003. [Clinical practice form]

**Le Jennifer.** Physiologic changes that affect drug dosing in the elderly. *Pharmacy Times*. December 2003;26-7. [Review article]

**Le Jennifer.** Fluoroquinolones: focus on safety profile. *Pharmacy Times*. September 2004;49-50. [Review article]

Medication facts. Adapted from American Academy of Pediatrics. Educational pamphlet for children and parents distributed at health fairs, 2004.

**Le Jennifer.** Revision of adult intravenous vancomycin guideline for pharmacist-regulated therapies. Peer-reviewed by Kildoo C, Ambrose P, and Strayer G. Approved by Pharmacy & Therapeutics Committee, October 2005. [Clinical practice guideline]

**Le Jennifer.** Acute otitis media. *Rx Consultant*. February 2008;17:1-6. [Review article]

**Le Jennifer,** Adler-Shohet F, Nguyen C and Lieberman J. Nephrotoxicity Associated with Conventional Amphotericin B in Neonates. 43rd Annual Meeting of the Infectious Diseases Society of America, October 6-9, 2005 - San Francisco; page 140.

Schieszer J. Vancomycin-related renal toxicity in children. *Renal and Urology News*. November 2009. [News article of research study]

**Le Jennifer** and Natale Stephanie. Pharmacokinetic alterations in obese children. Websites Part 1: <https://itunes.apple.com/us/podcast/episode-7-part-1/id1175416904?i=1000383843377&mt=2> and Part 2: <https://itunes.apple.com/us/podcast/episode-7-part-2/id1175416904?i=1000383843378&mt=2> [Invited by American College of Clinical Pharmacy for iTunes Podcast, 2015]

Rybak Michael and **Le Jennifer.** Consensus guidelines on therapeutic monitoring of vancomycin <http://www.ajhpvoices.org> [Invited by American Society of Health-System Pharmacists for Podcast, May 2020]

Rybak Michael, Tom Lodise and **Le Jennifer.** Twitter #VancoChat on consensus vancomycin [https://twitter.com/hashtag/VancoChat?src=hashtag\\_click](https://twitter.com/hashtag/VancoChat?src=hashtag_click) [Invited by American Society of Health-System Pharmacists and Society of Infectious Diseases Pharmacist, May 2020]

**Le Jennifer.** Excretion. <https://www.vitaglobalbrands.com/new-blog/excretion>

, Bradley JS, Nguyen WH, Tran TM, Ny P, La K, Vivian EM, and **Le Jennifer.** Pediatric obesity: pharmacokinetic alterations and effects on antimicrobial dosing. *Pharmacotherapy* 2017 Mar;37(3):361-378. [Review article]

**Le Jennifer**, Bradley JS. Optimizing Antibiotic Drug Therapy in Pediatrics: Current State and Future Needs. *J Clin Pharmacol* 2018;58 Suppl 10:S108-S122. [Review article]

Mashni O, Nazer L, and **Le Jennifer**. Critical Review of Double-Carbapenem Therapy for the Treatment of Carbapenemase-Producing *Klebsiella pneumoniae*. *Ann Pharmacotherapy* 2019;53(1):70-81. [Review article]

Nazer LH, **Le Jennifer**. Cost-effective Analysis of Low- versus High-dose Colistin in the Treatment of Multi-drug Resistant Pneumonia in Saudi Arabia. *Int J Clin Pharm.* 2019;41(1):1-2 [Letter to Editor]

Zeitlinger M, Koch BCP, Bruggemann R, Cock PD, Felton T, Hites M, **Le Jennifer** et al (listed in *alphabetical order* except for first and last authors). Pharmacokinetics/Pharmacodynamics of Antiviral Agents Used to Treat SARS-CoV-2 and Their Potential Interaction with Drugs and Other Supportive Measures: A Comprehensive Review by the PK/PD of Anti-Infectives Study Group of the European Society of Antimicrobial Agents. *Clin Pharmacokinet* 2020. <https://doi.org/10.1007/s40262-020-00924-9> [Review article]